| abstract |
The disclosure includes (a) compounds that inhibit HCV and salts thereof, (b) intermediates useful in the preparation of such compounds and salts, (c) compositions comprising such compounds and salts, (d) such intermediates. Methods for preparing bodies, compounds, salts and compositions, (e) methods of using such compounds, salts and compositions, and (f) kits containing such compounds, salts and compositions. |